Boeing posts nearly $3 billion quarterly loss
Boeing Co reported a nearly $3 billion loss for the second quarter on Wednesday, as it factored in a previously announced $5 billion charge related...
Trade talks buoy stocks, gloomy data sink euro
Global shares held on to recent gains on Wednesday as the prospect of new China-U.S. trade talks drew a guarded welcome from investors, while dour...
Russia, South Korea trade conflicting claims over alleged airspace intrusion
Russia’s embassy in Seoul on Wednesday said that Moscow had not apologized for an alleged airspace violation the previous day, after South Korea said that...
Drama in Washington as Mueller to testify; stakes high for Trump, Democrats
Former U.S. Special Counsel Robert Mueller testifies to Congress on Wednesday at a pair of televised hearings that carry high stakes for President Donald Trump...
Italy’s Salvini says sees ‘good signs’ of government moving forward
Italy’s Deputy Prime Minister Matteo Salvini said on Wednesday he saw “good signs” that the government was moving forward in his clearest statement yet that...
Nasdaq beats quarterly profit on strength in non-trading units
U.S. exchange operator Nasdaq Inc beat analysts’ estimates for second-quarter profit on Wednesday, as a boost in its non-trading businesses, including information services, overshadowed a...
Futures hit as DOJ aims antitrust probe at tech
U.S. stock index futures dropped on Wednesday, pressured by a fall in big tech companies after the announcement of a broad antitrust investigation by the...
AT&T wireless business grows but premium TV subscribers decline
AT&T Inc on Wednesday beat Wall Street estimates for net wireless subscribers who pay a monthly bill as it ground out some growth in a...
Nissan warns of profit plunge, set to unveil 10,000 job cuts
Nissan Motor Co Ltd warned on Wednesday that first-quarter profit tumbled around 90% percent, a day before it is expected to announce more than 10,000...
Samsung Bioepis Humira biosimilar wins FDA approval
(This story corrects to show that Hadlima belongs to Samsung Bioepis not Merck & Co Inc, which is commercializing the drug in the United States)...